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Introduction: DNA mutational profiling showed that
atypical carcinoids (ACs) share alterations with large cell
neuroendocrine carcinomas (LCNECs). Transcriptomic
studies suggested that LCNECs are composed of two sub-
types, one of which shares molecular anomalies with SCLC.
The missing piece of information is the transcriptomic
relationship between ACs and LCNECs, as a direct com-
parison is lacking in the literature.
Methods: Transcriptomic and genomic alterations were
investigated by next-generation sequencing in a discovery
set of 14 ACs and 14 LCNECs and validated on 21 ACs and
18 LCNECs by using custom gene panels and immunohis-
tochemistry for Men1 and Rb1.
Results: A 58-gene signature distinguished three tran-
scriptional clusters. Cluster 1 comprised 20 LCNECs and
one AC harboring concurrent inactivation of tumor protein
p53 gene (TP53) and retinoblastoma 1 gene (RB1) in the
absence of menin 1 gene (MEN1) mutations; all cases
lacked Rb1 nuclear immunostaining. Cluster 3 included 20Journal of Thoracic Oncology Vol. - No. -: ---
2 Simbolo et al Journal of Thoracic Oncology Vol. - No. -ACs and four LCNECs lacking RB1 alterations and having
frequent MEN1 (37.5%) and TP53 mutations (16.7%);
menin nuclear immunostaining was lost in 75% of cases.
Cluster 2 included 14 ACs and eight LCNECs showing in-
termediate features: TP53, 40.9%; MEN1, 22.7%; and RB1,
18.2%. Patients in cluster C1 had a shorter cancer-specific
survival than did patients in C2 or C3.
Conclusions: ACs and LCNECs comprise three different and
clinically relevant molecular diseases, one AC-enriched
group in which MEN1 inactivation plays a major role, one
LCNEC-enriched group whose hallmark is RB1 inactivation,
and one mixed group with intermediate molecular features.
These data support a progression of malignancy that may
be traced by using combined molecular and immunohisto-
chemical analysis.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Lung neuroendocrine tumors; Atypical carcinoid;
Large cell neuroendocrine carcinoma; Gene expression
profiling; Next-generation sequencing; Transcriptomics
Introduction
The current WHO classification divides lung neuro-
endocrine tumors (LNETs) into four histological variants:
typical carcinoid (TC), atypical carcinoid (AC), large cell
neuroendocrine carcinoma (LCNEC), and SCLC.1 From a
clinical standpoint, carcinoids (TCs and ACs) are distin-
guished from carcinomas (LCNEC and SCLC). TCs are
low-grade tumors, with patients having a long life ex-
pectancy, and ACs are intermediate-grade tumors with
varying clinical behavior. Conversely, LCNECs and SCLCs
are both high-grade tumors with a dismal prognosis.1–3
The insufficient knowledge of LNET biology limits the
comprehension of these tumor subtypes, which to date
have been considered as having a separate pathogen-
esis.4–7 Recent DNA mutational profiles showed that
carcinoids and carcinomas share similar gene alterations,
but with different prevalence among the subtypes.8 Al-
terations in chromatin remodeling genes are found in all
four variants, whereas menin 1 gene (MEN1) alterations
are found mainly in carcinoids, and inactivation of tumor
protein p53 gene (TP53) and retinoblastoma 1 gene (RB1)
is significantly enriched in carcinomas.5,8–12 The fact that
the same gene alterations found in carcinomas are iden-
tified in low-grade tumors but at a lower prevalence may
suggest the existence of progression of malignancy and
the development of secondary high-grade neuroendo-
crine carcinomas from preexisting carcinoids.8,13
Gene expression profiles produce a global picture
of cellular function, and it has been shown that thetranscriptional phenotypes of lung cancers mimic the
WHO classification.6,14 They may also provide additional
stratification within histological subtypes (that is, the
potential to identify molecular subgroups within tumors
showing similar morphological features).14,15
Three gene expression profiling studies of LNETs
have been recently published.9,14,16 Asiedu et al. re-
ported that transcriptomic profiles could distinguish
between carcinoids (TCs and ACs) and SCLC16; in this
study LCNECs were not included. Karlsson et al.
analyzed an ample series of large cell lung carcinomas,
including LNECs, and observed a clear separation of
three transcriptional groups: adenocarcinoma, squa-
mous cell carcinoma, and a third neuroendocrine group
comprising SCLC and LCNEC.14 Moreover, the compari-
son of LCNEC and SCLC showed that LCNEC exhibited
two different transcriptional profiles associated with
different TP53 and RB1 genes alteration patterns, cor-
responding to a proposed genetic division of LCNEC into
SCLC-like and NSCLC-like cancers.14 A study of 75
LCNECs by George et al. confirmed the existence of two
LCNEC subtypes, one (type II) characterized by the
concurrent inactivation of TP53 and RB1 (42%) and one
(type I) with TP53 and serine/threonine kinase 11 gene
(STK11)/kelch like ECH associated protein 1 gene
(KEAP1) alterations (37%), but clearly showed that
LCNECs have no transcriptional relationship with ade-
nocarcinomas and squamous cell carcinomas.9
The missing piece of information is the tran-
scriptomic relationship between AC and LCNEC, as a
direct comparison, is lacking in the literature.Materials and Methods
Cases
A cohort of 67 surgically resected LNETs was
collected from four Italian institutions (Applied Rea-
search on Cancer-Network [ARC-Net] Research Centre-
Verona, IRCCS San Martino-Genova, University of Pisa,
and AUO Orbassano-University of Turin). All cases were
reclassified according to the WHO 2015 criteria1 and
included 35 ACs and 32 LCNECs. Neuroendocrine
differentiation was assessed by using immunostaining
for chromogranin, synaptophysin, and CD56.1,17,18 The
AC diagnostic criteria included a well-differentiated
morphology with between two and 10 mitoses per 2
mm2 of area and/or presence of focal necrosis.19,20
LCNECs were diagnosed on the basis of non–small cell
cytologic features, including large cell size, low nuclear-
to-cytoplasmic ratio, prominent nucleoli or vesicular
chromatin, a mitotic rate of more than 10 mitoses per 2
mm2 (average 60–80 mitoses per 2 mm2), and more
extensive necrosis.18–20 Tumor stage was assigned ac-
cording to the seventh edition of the TNM classification
--- 2019 AC and LCNEC Integrative Molecular Analysis 3of malignant tumors.21 None of the patients received
preoperative therapy. Samples were divided into two
groups: a discovery set including 28 samples (14 ACs
and 14 LCNECs) and a validation set of 39 samples
(21 ACs and 18 LCNECs).
Ethics
Ethics committee approval (ECA) was obtained at
the four institutions: ARC-Net Research Centre-Verona
(ECA no. 2173-prot.26775 [1 June 2012]), AUO
Orbassano-University of Torino (ECA no. 167/2015-prot.
17975 [October 21, 2015]), IRCCS San Martino-Genova
(ECA no. 027/2016LM [16 March 2016]), and Univer-
sity of Pisa [ECA no. 1040/16 [March 31, 2016]).
Mutational, CNV, and Expression Analysis by
Next-Generation Sequencing
The details of the experimental procedures are
described in the Supplementary Methods. Briefly, nucleic
acids were obtained from formalin-fixed paraffin-
embedded tissues as reported.22,23 Sequencing was per-
formed on Ion Torrent platform (Thermo Fisher Scienti-
fic). Data analysis including variant calling was done
by using Torrent Suite Software, version 5.0 (Termo
Fisher Scientific). Unfiltered variants are reported in
Supplementary Tables 1 and 2. Filtered variants were
annotated by using a custom pipeline based on vcflib
(https://github.com/ekg/vcflib), SnpSift,24 and Variant
Effect Predictor.25 Annotated variants were filtered by
using only the canonical transcripts. Only missense,
nonsense, frameshift, or splice site variants were
retained. Germline variants were removed. Alignments
were visually verified with the Integrative Genomics
Viewer, version 2.3,26 to confirm the presence of identi-
fied mutations and to exclude sequencing artefacts. The
mutational profile27 of each sample was obtained with
the MuSiCa software.28 Copy number variation (CNV)
was evaluated by using OncoCNV software, version 6.8.29
The AmpliSeqRNA plugin was used to analyze expression
profiling data. Differential analysis was performed by
using the DESeq230 package for R; an adjusted p value
less than 0.05 was considered significant. For gene set
analysis, the GSVA31 package was used.
Immunohistochemistry
Immunostaining was performed by using the Bond
Polymer Refine Detection kit (Leica Biosystems) in a
BOND-MAX system (Leica Biosystems) on 4-mm-thick
formalin-fixed paraffin-embedded sections with the pri-
mary antibodies for menin (clone A300-105A [Bethyl
Laboratories], dilution 1:1000) and Rb (clone 4H1 [Cell
Signaling Technology], dilution 1:250). Appropriate
positive and negative controls were run concurrently.Statistical Analysis
One-way analysis of variance, the Kruskal-Wallis test,
the Fisher test with Monte Carlo simulation, and the
Fisher exact test were used as appropriate; correction
for multiple comparisons was performed according to
Benjamini-Hochberg. The Mantel-Cox test was used to
compare survival curves. A p value less than 0.05 was
considered as significant. Analyses were performed by
using Medcalc for Windows, version.18.11 (MedCalc
Software), and R software, version 3.5.3.32
Results
Study Design
The cohort of 67 cases was divided into a discovery
set and a validation set, consisting of 28 and 39 cases,
respectively. The study workflow is depicted in
Supplementary Figure 1.
The discovery screen was performed on 14 ACs and
14 LCNECs with use of the Ampliseq Transcriptome
Human Gene Expression Kit (ThermoFisher), which in-
vestigates the expression of 20,815 human genes, and
the Ampliseq Comprehensive Cancer Panel (Thermo-
Fisher) for mutational and CNV analysis of 409 genes.
The validation set comprised 21 ACs and 18 LCNECs
and was analyzed by targeted sequencing with the use of
two custom panels. The first panel was designed to
assess the mRNA expression level of 60 genes, including
58 that were differentially expressed in the discovery set
plus MEN1 and RB1. The second panel was devised to
evaluate DNA alterations in 16 genes: seven genes for
mutational analysis only, three genes for CNV analysis
only, and six genes for both mutational and CNV analysis.
The expression profiles clustering analysis and the
prevalence of mutations and CNVs were finally
computed on the entire cohort of 67 cases.
Clinicopathologic Features
Clinicopathologic data are summarized in
Supplementary Table 3 and detailed in Supplementary
Table 4. The 67 patients had a mean age of 66.2 years
and a median clinical follow-up time of 17 months
(range 2–100). Of the 67 cases, 33 (49%) were stage I,
24 (36%) stage II, six (9%) were stage III, and four (6%)
were stage IV. ACs and LCNECs differed by patient age,
patient sex, tumor size, and Ki67 index, whereas there
was no statistically significant difference for smoking
status and stage (see Supplementary Table 3).
Gene Expression Analysis and Unsupervised
Hierarchical Clustering of Discovery Set
Gene expression analysis was performed on the 28
samples of the discovery set and eight nonneoplastic lung
samples. Hierarchical unsupervised clustering analysis
Figure 1. Transcriptome analysis of the discovery set of 28 lung neuroendocrine neoplasms distinguished three molecular
clusters of tumors. (A) Hierarchical unsupervised clustering of transcriptomes of 14 atypical carcinoids (ACs) (green) and 14
large cell neuroendocrine carcinomas (LCNEC) (orange) plus eight normal lung (N) (light blue) samples with use of the Ward D2
algorithm Tumors were grouped in three separate clusters (C1, C2, and C3) that differ from normal lung samples. Case ID is
indicated at the bottom, gene names are indicated on the right. (B) Alterations in 16 genes at sequencing analysis; the legend
for pathological and molecular alterations is reported in the panel on the right. The mutation spectrum takes into consider-
ation all nonsynonymous variants detected per megabase of exonic sequence, grouped into six classes; stacked bars represent
the percentage of each group in each sample. (C) Copy number variations within the three clusters (left panel) refer to
chromosomes; frequency of copy number variation alterations (right panel) where copy gain events are indicated in red and
losses in blue. TP53, tumor protein p53 gene; RB1, retinoblastoma 1 gene;MEN1, menin 1 gene; NOTCH2, notch 2 gene; STK11,
serine/threonine kinase 11 gene; SMARCA2, SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily a, member 2 gene; SMARCA4, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, sub-
family a, member 4 gene; MYCL1, v-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog gene;
MYC, v-myc avian myelocytomatosis viral oncogene homolog gene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha gene; KMT2D, lysine methyltransferase 2D gene; PTEN, phosphatase and tensin homolog gene;
KMT2C, lysine methyltransferase 2C gene; CDKN2A, cyclin dependent kinase inhibitor 2A gene; KEAP1, kelch like ECH asso-
ciated protein 1 gene; ARID1A, AT-rich interaction domain 1A gene; BAP1, BRCA1 associated protein 1 gene; TERT, telomerase
reverse transcriptase; APC, APC, WNT signaling pathway regulator; FGRF1, gene; CCND2, cyclin D2 gene; NKX2-1, NK2
homeobox 2 gene; SRC, SRC proto-oncogene, non-receptor tyrosine kinase gene; CHEK2, checkpoint kinase 2 gene.
4 Simbolo et al Journal of Thoracic Oncology Vol. - No. -using the Ward D2 algorithm identified four clusters
(Fig. 1A): cluster 1 (C1), which included 12 samples (11
LCNECs and one AC); cluster 2 (C2), which included five
samples (all ACs); cluster 3 (C3) , which included 11samples (eight ACs and three LCNECs); and a fourth group
(N), which included all nonneoplastic lung samples.
To verify the robustness of clusters, nonnegative
matrix factorization (NMF) based on the expression
--- 2019 AC and LCNEC Integrative Molecular Analysis 5profile of the top varying 5000 genes was performed
(Supplementary Fig. 2). NMF supported the presence of
three LNET classes and one class of normal samples
(Supplementary Fig. 2A). Comparison of the four NMF
classes versus the four hierarchical clustering clusters
showed that 32 of 35 cases (91.4%) were consistently
assigned to corresponding groups (Supplementary
Fig. 2B), confirming the reliability of clusters.
To analyze differentially affected pathways, gene set
variation analysis was performed31 aggregating gene
expression data according to the “hallmark” gene sets
collection from the Molecular Signatures Database
(http://software.broadinstitute.org/gsea/msigdb). Gene
set variation analysis identified differentially enriched
gene sets between tumor clusters (Supplementary Fig. 3).
In particular, the gene sets of E2F targets and G2/M
checkpoint showed a progressively higher score moving
from cluster C3 toward cluster C1 (p < 0.001). The E2F
targets gene set includes downstream targets of the E2F
transcription factors family, which play a major role in
G1/S transition.33 Similarly, genes of the G2M checkpoint
set mediate progression through the cell cycle. Thus,
coordinated enrichment of both sets is consistent with
increased proliferation.
Conversely, the bile acid metabolism gene set,
including members involved in peroxisome organization,
was increasingly up-regulated moving from C1 to C3
(p ¼ 0.0217). A similar trend was also observed in the
other gene sets enriched at a false discovery rate of 0.1.
Indeed, genes involved in the mitotic spindle and v-myc
avian myelocytomatosis viral oncogene homolog gene
(MYC) targets were enriched in C1, consistent with
recurrent MYC copy gain in this cluster, whereas gene
sets related to bile acid metabolism (fatty acid meta-
bolism, xenobiotic metabolism, and peroxisome) were
enriched in C3. Finally, C1 and C2 displayed enrichment
in Wnt signalling compared with C3 (Supplementary
Table 5 and see also Supplementary Fig. 3).
A set of 58 genes was identified as differentially
expressed among the three clusters (p < 0.05). The de-
tails on differentially expressed genes are reported in
Supplementary Table 6 and their distribution in the
three LNET clusters in Supplementary Figure 4.A 58-Gene Signature Identifies Three Expression
Profiling Clusters with Distinct Clinicopathologic
Features
An RNA targeted sequencing custom panel, designed
by using the 58-gene signature identified in the discovery
set, was used to analyze the entire series of 67 cases (35
ACs and 32 LCNECs) comprising the 28 of the discovery
set and the 39 of the validation set. Additionally, MEN1
and RB1 transcripts were included in the custom panelbecause of their known involvement in AC and LCNEC,
respectively,9,14,34 to correlate their expression levels
with the mutational status.
Hierarchical clustering using the 58 genes and Ward
D2 algorithm categorized the cases in three clusters
(Fig. 2), which were consistent with those obtained by
the analysis of 20,815 genes in the discovery set. Clini-
copathologic features of the 67 cases are compared
across the three clusters in Table 1. Cluster 1 contained
20 LCNECs and one AC. This cluster showed a higher
Ki67 index (mean 66% [p < 0.0001]) and shorter
cancer-specific survival (p ¼ 0.26). C3 included 20 ACs
and four LCNECs characterized by a lower Ki67 index
(mean 21%) and did not reach the median cancer-
specific survival (Supplementary Fig. 5). C2 included
14 ACs and eight LCNECs showing intermediate features
between those in C1 and C3, with a mean Ki67 index of
36% and a median cancer-specific survival of 47 months.
Remarkably, this intermediate C2 cluster was composed
of two subclusters (see Fig. 2). C2a included eight
LCNECs and three ACs, the former characterized by TP53
mutations in all eight cases associated with a heterozy-
gous RB1 mutations in four of them, whereas one of the
three ACs had a MEN1 mutation. C2b included 11 ACs,
four of which harbored a MEN1 mutation and one had a
TP53 mutation. The Ki67 index in C2a (mean 60.0, me-
dian 60.0, range 10%–80%) was higher than in C2b
(mean 12.0; median 7.0; range 3-35%).
MEN1 and RB1 expression levels were differentially
distributed among the clusters, with significant under-
expression of RB1 in all C1 cases and significant under-
expression of MEN1 in most of the C3 samples and
one-third of the C2 samples (Fig. 3A).Discovery Screen of Mutations and CNVs of 14
ACs and 14 LCNECs
Mutational analysis was performed on the discovery
set for the coding sequence of 409 genes. Sequencing
achieved an average coverage of 698 (198–1657)
in tumor and 386 (26–981) in normal samples
(Supplementary Table 7).
Mutations were identified in 22 of the 28 cases. All
12 cases in C1 harbored mutations, whereas two of five
cases in C2 and four of 11 in C3 had no mutations. A
total of 79 mutations were identified in 36 genes: 56
missense, 10 nonsense, eight frameshift, and five splice
site (Supplementary Table 8). TP53 was the most
frequently mutated gene (13 of 28 [46.4%]), followed
by RB1 (11 of 28 [39.3%]), notch 2 gene (NOTCH2)
(five of 28 [17.9%]), and MEN1 (four of 28 [14.3%])
(Fig. 1B). The mutational spectrum was prevalently
characterized by T>C and C>T transitions, with
different relative contributions in individual tumors.
Figure 2. Validation analysis on 67 lung neuroendocrine neoplasms confirms the existence of three clusters of tumors. (A)
Hierarchical clustering of 35 atypical carcinoids (ACs) and 32 large cell neuroendocrine carcinomas (LCNECs) with use of an
RNA custom panel of 58 genes confirmed the presence of the three different molecular subgroups identified by whole
transcriptome analysis (see Fig. 1 and Supplementary Fig. 4) and suggests further splitting of cluster 2. (B) Clinicopathologic
features of the 67 samples; the legend for clinical pathological and molecular alterations is reported in the panel on the right.
(C) The 16 genes that were altered at sequencing analysis; the legend for alteration type is reported in the panel on the right.
(D) Immunohistochemical analysis data of menin and Rb.
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[T>C]G, followed by A[T>C]G and A[C>T]G. In
particular, all three clusters showed C[T>C]G as the
most frequent substitution. The A[T>C]G substitution
was the second most frequent in C1 and C2 but not in
C3, in which the second most frequent substitution was
A[C>T]G. However, no specific substitution was pre-
dominant in any cluster.
The CNV status was estimated for all 409 genes by
using sequencing data (Supplementary Table 9). Themost frequently altered were 20 genes (Supplementary
Table 10), including gains in succinate dehydrogenase
complex flavoprotein subunit A gene (SDHA), RPTOR
independent companion of MTOR complex 2 gene (RIC-
TOR), telomerase reverse transcriptase gene (TERT) (12
of 28 each [42.9%]), and MYC (11 of 28 [39.3%]) and
losses in BRCA1 associated protein 1 gene (BAP1) (12 of
28 [42.9%]), RB1 (10 of 28 [35.7%]), and MEN1 (eight of
28 [28.6%]). On the basis of the chromosomal position of
each gene, the status of chromosome arms was inferred
Figure 3. mRNA and immunohistochemical expression analysis of MEN1 and RB1. (A) Expression levels (natural logarithm
values on y axes) of menin 1 gene (MEN1) and retinoblastoma 1 gene (RB1) genes in the three molecular clusters (on x axes)
identified by gene expression profiling (see Fig. 2); the dashed red line represents the average gene expression across the
entire cohort (reference line). (B) Representative images of positive and negative nuclear immunostaining for menin and Rb
proteins in two cases harboring a truncating mutation of the corresponding gene, namely Cys235* truncating mutation in
MEN1 gene and Arg255* truncating mutation in RB1 gene. (scale bars ¼ 100 mm; original magnifications, 10 and 40 [inset]).
--- 2019 AC and LCNEC Integrative Molecular Analysis 7(Fig. 1C and Supplementary Table 11). Such analysis
showed major alterations, namely, losses of chromosome
arm 3p (14 of 28 [50.0%]) and whole chromosomes 18
(11 of 28 [39.3%]) and 11 (nine of 28 [32.1%]) and
gains in chromosome arms 8q (12 of 28 [42.9%]) and 5p
(11 of 28 [39.3%]). Chromosome alterations according
to tumor type and expression profile clusters are illus-
trated in Supplementary Figure 6.
Validation of Mutations and CNVs in 21 ACs and
18 LCNECs by Targeted Sequencing of 16 Genes
The validation set was analyzed by targeted
sequencing using a DNA custom panel of 16 genes
altered in both the present study and other studies
investigating LNETs,5,9,16,35 investigating the mutational
status of seven genes, CNV of three genes, and both al-
terations of six genes (Supplementary Table 12).
Sequencing achieved an average coverage of 1649
(329–3636) in tumor and 468 (165–1643) in
normal samples (see Supplementary Table 7). A total of
67 mutations were identified: 38 missense mutations,
13 nonsense mutations, 11 frameshift mutations, threein-frame deletions, and two splice site mutations (see
Supplementary Table 8). TP53 was the most frequently
mutated gene (20 of 39 [51.3%]), followed by MEN1 (10
of 39 [25.6%]) and RB1 (nine of 39 [23.1%]).
Analysis of CNV status for the nine selected genes
identified gains in MYC (five of 39 [12.8%]) and losses in
RB1 (four of 39 [10.3%]) as the most frequent alter-
ations. The comparison between discovery and valida-
tion set is reported in Supplementary Table 13.
Prevalence of Gene Mutations and Copy Number
Alterations in the Three Different Molecular
Clusters
Considering the whole series of 67 cases (35 ACs and
32 LCNECs), the three expression profile clusters
showed differences in mutation and CNV frequency for
specific genes (Fig. 2C). Mutations were present in 56 of
67 cases (see Supplementary Table 8). All 21 patients in
C1 harbored mutations, whereas three of 22 in C2 and
eight of 24 in C3 had no mutations. Different distribu-
tions were identified for TP53 and RB1 alterations (each
p < 0.0001), SWI/SNF related, matrix associated, actin
8 Simbolo et al Journal of Thoracic Oncology Vol. - No. -dependent regulator of chromatin, subfamily a, member
2 gene (SMARCA2) (p ¼ 0.043) and MEN1 (p ¼ 0.008)
mutations, and phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit alpha gene (PIK3CA) (p ¼ 0.035)
alterations (Table 2). C1 was characterized by concur-
rent TP53 and RB1 alterations (21 of 21; 100%); also
peculiar to this cluster were alterations in PIK3CA (five
of 21 [23.8%], p ¼ 0.038) and SMARCA2 (four of 21
[19.0%], p ¼ 0.047). C2 showed TP53 alterations as the
most frequent event (nine of 22 [40.9%]), followed by
MEN1 (five of 22 [22.7%]) and RB1 (four of 22 [18.2%]).
C3 had MEN1 mutation as the most frequent event (nine
of 24 [37.5%]), followed by TP53 alterations (four of 24
[16.7%]), whereas no RB1 anomaly was displayed.Expression Levels and Immunohistochemistry of
Menin and Rb
Menin and Rb mRNA levels were assessed in all 67
samples. For each sample, normalized log-transformed
next-generation sequencing counts were compared be-
tween mRNA expression clusters by Kruskal-Wallis test.
RB1 and MEN1 mRNAs showed differential expression
between clusters (each p < 0.0001) (see Fig. 3A). In
particular, MEN1 mRNA level was very low in 24 sam-
ples, of which 17 were in C3 (17 of 24; 70.8%) and seven
were in C2 (seven of 22; 31.8%), whereas RB1 mRNA
level was very low in all C1 samples (see Fig. 3A). All 14
samples harboring MEN1 mutations showed very low
MEN1 mRNA.
All cases were immunostained for menin and Rb, and
nuclear negativity was interpreted as abnormal (repre-
sentative cases in Fig. 3B). Both MEN1 and RB1 dis-
played strong correlation between mRNA levels and
protein immunolabeling (p < 0.00001 [Supplementary
Fig. 7]).
Lack of menin nuclear immunostaining was detec-
ted in 24 of 67 cases (35.8%), including the seven
samples in C2 and the 17 in C3 that had low mRNA
levels, whereas all cases in C1 had positive immuno-
staining. A direct correlation between presence of
mutations, low mRNA level, and loss of protein nuclear
immunostaining was observed (p < 0.0001). In detail,
all 14 cases with MEN1 mutation, including 11 ACs and
three LCNECs, had low mRNA levels and negative nu-
clear immunostaining; of these 14 cases, the three
LCNECs and six ACs were in C3 whereas five ACs were
in C2. Interestingly, 10 cases were wild-type for MEN1
at sequencing; nine ACs belonging to C3 and one
LCNEC belonging to C2, showed loss of nuclear menin,
suggesting the existence of additional mechanisms
of MEN1 inactivation.34 All cases in C1 were MEN1
wild-type at sequencing and had positive menin
immunostaining.36Lack of Rb nuclear immunostaining was found in all
21 samples of C1 (20 LCNECs and one AC), with
concomitant low mRNA levels and biallelic inactivation
of RB1 owing to homozygous deletion in five cases or
heterozygous mutation and loss of the wild-type allele in
16 cases (Supplementary Table 14 and see also Fig. 2).
Conversely, all samples in C2 and C3 had positive nu-
clear immunostaining, including four cases in C2 with
RB1 heterozygous mutations and retention of the wild-
type allele.
Discussion
It has been suggested that high-grade neuroendo-
crine carcinomas may represent a progression of ma-
lignancy of preexisting carcinoids.13 Indeed, recent
genomic and transcriptomic data indicate that ACs are
hybrid tumors sharing genomic features with both low-
grade (TCs) and high-grade (LCNECs and SCLCs)
neuroendocrine neoplasms,8 and that LCNECs may be
subdivided in at least two molecular subgroups, one of
which shows molecular similarities with SCLCs.7,9,14 This
prompted us to perform a direct comparison of molec-
ular alterations of ACs and LCNECs, which is lacking in
literature.
The comparative transcriptomic analysis of ACs and
LCNECs reported herein discriminated three transcrip-
tional clusters, defined as C1, C2, and C3, which also
showed specific genomic patterns (Fig. 4).
C3 was an AC-enriched cluster that included 20 ACs
(83.3%) and four LCNECs (16.7%). MEN1 mutations
were the most frequent events (nine of 24 [37.5%]),
followed by TP53 mutations (16.7%). No case had RB1
alterations. Interestingly, three of the four LCNECs in this
cluster harbored MEN1 mutations, which are relatively
rare in LCNECs, in which they account for 4% of
cases.8,35 That MEN1 alterations may represent a major
event in this cluster is suggested by loss of menin nu-
clear immunostaining in most cases (18 of 24 [75.0%]),
including nine samples harboring a MEN1 mutation and
nine that were determined to be wild-type, suggesting
the existence of additional inactivation mechanisms.34
Indeed, the immunohistochemical findings in LNETs of
the present series parallel those in pancreatic neuroen-
docrine neoplasms, in which of 80% of cases lacking
menin nuclear immunostaining, only 30% revealed
MEN1 mutations by sequencing analysis,36 and subse-
quent whole-genome analysis showed gross chromo-
some 11 alterations in many cases.37
C1 was an LCNEC-enriched cluster consisting of 20
LCNECs and one AC. All cases in this cluster had con-
current inactivation of TP53 and RB1 genes (100%) and
lacked MEN1 mutations. All samples showed low RB1
mRNA and loss of nuclear immunostaining for Rb pro-
tein. Other frequent alterations in C1 were found in
Figure 4. Outline of main differences between the three clusters of the lung neuroendocrine tumors. Cluster 3 is mainly
composed of atypical carcinoids (ACs), is Rb proficient, features frequent menin 1 gene (MEN1) and rare retinoblastoma 1
gene (TP53) mutations, and displays high levels of oxidative metabolism. Cluster 1 is composed almost exclusively of large
cell neuroendocrine carcinomas (LCNECs), has Rb loss of expression, always features TP53 and RB1 inactivation, and displays
high levels of cell cycle deregulation. Cluster 2 has an intermediate transcriptional profile compared with C1 and C3 and is
composed of both ACs (one-third of which bear a MEN1 mutation) and LCNECs (featuring TP53 mutation but retaining Rb
expression). profile: neg, negative staining in all cases; low, negative staining in most cases; mid, similar proportion of
positive and negative cases; high, positive staining in most cases; mut, mutation; MYC, v-myc avian myelocytomatosis viral
oncogene homolog gene.
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myelocytomatosis viral oncogene lung carcinoma
derived homolog gene (MYCL1) (each 14.3%) genes.
C2 showed intermediate features between C1 and C3.
This group included 14 ACs (64%) and eight LCNECs
(36%), in which mutations in TP53 was the most
frequent event (41%), followed by mutations in MEN1
(23%) and RB1 (18%) genes. Menin nuclear immuno-
staining was lost in six samples, comprising the five
harboring MEN1 mutations and one MEN1 wild-type.
Interestingly, nuclear immunostaining of Rb was
retained in all cases in this cluster, including the four
that harbored a mutated allele but retained the normal
allele, supporting the central role of the biallelic inacti-
vation of RB1 in the transcriptomic shift from C2 to C1.
A comparison of our clusters with the subsets of
Rekhtman et al.,35 and George et al.,9 both comprising
only LCNECs, has identified some interesting overlap. Of
note, Rekhtman et al. defined those LCNECs harboring
MEN1 mutations as a third minor subset of “carcinoid-
like” LCNECs, and these cases were part of our AC-
predominant C3.35 Our C1 LCNEC-enriched cluster with
concurrent inactivation of TP53 and RB1 genes andlacking MEN1 mutations coincide with both the SCLC-
like LCNEC subtype of Rekhtman et al.35 and the type
II LCNECs of George et al.9 Interestingly, other frequent
alterations found in our C1 were SMARCA2, STK11,
KEAP1, and MYCL1. As these genes are frequently altered
in NSCLCs, Rekhtman et al. classified cases harboring
these alterations and lacking concurrent RB1/TP53
inactivation as NSCLC-like LCNEC.35 Similarly, George
et al. suggested that these alterations are typical of their
type II LCNECs, but clearly reported that they had no
transcriptional relationship with NSCLCs.9 Furthermore,
inactivation of TP53 with retained Rb immunostaining
notable to our C2, are characteristics of the NSCLC-like
subtype of Rekhtman et al. and the type I of George
et al.9,35 Notably, our finding that these alterations may
occur in association with concurrent RB1/TP53 inacti-
vation is not surprising, as several cases in the series of
both Rekhtman et al. and George et al. displayed the
same phenomenon.9,35
The identification of three clusters of ACs and
LCNECs, two of which were enriched for either AC or
LCNEC and the third with intermediate features, sug-
gests the existence of a progression of malignancy for a
10 Simbolo et al Journal of Thoracic Oncology Vol. - No. -proportion of ACs into LCNECs. This is further supported
by the fact that the intermediate C2 cluster was
composed of two subclusters. The first (C2a) was closer
to C1 because of both a similarly high Ki67 index (mean
60%) and the presence of LCNECs with TP53 mutations
associated with heterozygous RB1 alterations. The sec-
ond (C2b), which is closer to C3, is composed entirely of
ACs with a mean Ki67 index of 12% and enriched for
MEN1 mutations. The ACs in C2, especially those sharing
the C2a subcluster with LCNECs, might overlap with the
recently proposed “supracarcinoids,” which were iden-
tified by Alcala et al. through supervised machine
learning of genomic and transcriptomic data.38 Indeed,
supracarcinoids were defined as a subgroup of LNETs
with a clear carcinoid histopathologic pattern but with
molecular characteristics similar to those of LCNECs.38
This further supports the hypothesis that carcinoids
may evolve into carcinomas by accumulation of genetic
anomalies. A recent publication explicitly suggested the
existence of an evolution from AC to LCNEC on the basis
of clustering of mutations and CNVs.13 This might be
especially true for a fraction of ACs that do not display
MEN1 loss but show TP53 alterations.
The three clusters described here also differed from a
clinicopathologic point of view, including Ki67 prolifer-
ation index and cancer-specific survival. C1 had a mean
Ki67 index of 66% versus 37% and 21% for C2 and C3,
respectively. Follow-up data were available for 56 pa-
tients. Patients in C1 had the shortest survival (median
19 months), whereas patients in C2 had a median sur-
vival of 47 months and patients in C3 did not reach the
median survival during follow-up.
In conclusion, our study shows that ACs and LCNECs
comprise three different molecular diseases of potential
clinical relevance, one AC-enriched group in which MEN1
inactivation plays a major role, one LCNEC-enriched
group whose hallmark is RB1 inactivation, and one
group with intermediate features. Indeed, it has been
reported that carcinoids harboring MEN1 mutations, loss
of heterozygosity, and low mRNA levels had shorter
overall survival,34 whereas the independent poor prog-
nostic role of RB1 inactivation is common to AC, LCNEC,
and SCLC.8 Molecular profiling with a combined immu-
nohistochemical and mutational analysis using routinely
available paraffin-embedded tissues may complement
histological examination to provide better diagnostic
definition and prognostic stratification of LNETs that
would be helpful for their clinical management.
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